Review





Similar Products

95
Santa Cruz Biotechnology mouse anti tubβ3
Mouse Anti Tubβ3, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti-%CE%B23+tubulin/bio_rxiv__64898__2026__03__29__715159-52-10-14?v=Santa+Cruz+Biotechnology
Average 95 stars, based on 1 article reviews
mouse anti tubβ3 - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier

95
Cell Signaling Technology Inc mouse anti β3 tubulin
Mouse Anti β3 Tubulin, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti-%CE%B23+tubulin/pm41643835-79-27-31?v=Cell+Signaling+Technology+Inc
Average 95 stars, based on 1 article reviews
mouse anti β3 tubulin - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier

95
Santa Cruz Biotechnology mouse monoclonal anti βlll tubulin antibody
(A) Experimental design for early-neuron marker <t>βIII-tubulin</t> detection, time course for sample acquisition and chemical treatment. (B) Representative immunofluorescences of MG at 48 h after treatments, cultured in basal growth media, CTRL: control, NMDA: exposure to NMDA 100 µM, MOCK: electroporation without plasmid, dCas9: transfection of empty plasmid, DNMT3a KD: CRISPR interference-mediated Dnmt3a knockdown, DNMT3a KD NMDA: Dnmt3a knockdown with simultaneous exposure to NMDA 100 µM; show GS (red), βIII-tubulin (green), and nuclei (DAPI, blue). (C) Percentage of positive cells to GS and βIII-tubulin, where all conditions present constant expression of GS, while βIII-tubulin percentage of positive cells were increased in DNMT3a KD and DNMT3a KD NMDA. (D) Quantification of fluorescence intensity of GS marks at 48 h after treatment, no significant differences were observed across conditions. (E) Quantification of fluorescence intensity of βIII-tubulin shows an increase in DNMT3a KD and DNMT3a KD NMDA groups, consistent with the increase in βIII-tubulin percentage of positive cells. Scale bars = 20 µm, 40X. Percentage of positive cells for each marker were presented as bar graphic for mean ± SEM from three independent experiments, counting a minimum of 10 non-overlapped fields and at least 150 cells per group. *p < 0.05, **p < 0.01, ns = no significant (one-way ANOVA with Tukey post hoc test).
Mouse Monoclonal Anti βlll Tubulin Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti-%CE%B23+tubulin/pmc12711019-135-10-15?v=Santa+Cruz+Biotechnology
Average 95 stars, based on 1 article reviews
mouse monoclonal anti βlll tubulin antibody - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier

95
Santa Cruz Biotechnology mouse anti β3 tubulin antibody
(A) Experimental design for early-neuron marker <t>βIII-tubulin</t> detection, time course for sample acquisition and chemical treatment. (B) Representative immunofluorescences of MG at 48 h after treatments, cultured in basal growth media, CTRL: control, NMDA: exposure to NMDA 100 µM, MOCK: electroporation without plasmid, dCas9: transfection of empty plasmid, DNMT3a KD: CRISPR interference-mediated Dnmt3a knockdown, DNMT3a KD NMDA: Dnmt3a knockdown with simultaneous exposure to NMDA 100 µM; show GS (red), βIII-tubulin (green), and nuclei (DAPI, blue). (C) Percentage of positive cells to GS and βIII-tubulin, where all conditions present constant expression of GS, while βIII-tubulin percentage of positive cells were increased in DNMT3a KD and DNMT3a KD NMDA. (D) Quantification of fluorescence intensity of GS marks at 48 h after treatment, no significant differences were observed across conditions. (E) Quantification of fluorescence intensity of βIII-tubulin shows an increase in DNMT3a KD and DNMT3a KD NMDA groups, consistent with the increase in βIII-tubulin percentage of positive cells. Scale bars = 20 µm, 40X. Percentage of positive cells for each marker were presented as bar graphic for mean ± SEM from three independent experiments, counting a minimum of 10 non-overlapped fields and at least 150 cells per group. *p < 0.05, **p < 0.01, ns = no significant (one-way ANOVA with Tukey post hoc test).
Mouse Anti β3 Tubulin Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti-%CE%B23+tubulin/pm41391557-98-6-11?v=Santa+Cruz+Biotechnology
Average 95 stars, based on 1 article reviews
mouse anti β3 tubulin antibody - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier

95
Santa Cruz Biotechnology mouse
(A) Experimental design for early-neuron marker <t>βIII-tubulin</t> detection, time course for sample acquisition and chemical treatment. (B) Representative immunofluorescences of MG at 48 h after treatments, cultured in basal growth media, CTRL: control, NMDA: exposure to NMDA 100 µM, MOCK: electroporation without plasmid, dCas9: transfection of empty plasmid, DNMT3a KD: CRISPR interference-mediated Dnmt3a knockdown, DNMT3a KD NMDA: Dnmt3a knockdown with simultaneous exposure to NMDA 100 µM; show GS (red), βIII-tubulin (green), and nuclei (DAPI, blue). (C) Percentage of positive cells to GS and βIII-tubulin, where all conditions present constant expression of GS, while βIII-tubulin percentage of positive cells were increased in DNMT3a KD and DNMT3a KD NMDA. (D) Quantification of fluorescence intensity of GS marks at 48 h after treatment, no significant differences were observed across conditions. (E) Quantification of fluorescence intensity of βIII-tubulin shows an increase in DNMT3a KD and DNMT3a KD NMDA groups, consistent with the increase in βIII-tubulin percentage of positive cells. Scale bars = 20 µm, 40X. Percentage of positive cells for each marker were presented as bar graphic for mean ± SEM from three independent experiments, counting a minimum of 10 non-overlapped fields and at least 150 cells per group. *p < 0.05, **p < 0.01, ns = no significant (one-way ANOVA with Tukey post hoc test).
Mouse, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti-%CE%B23+tubulin/pmc12692065-8-2-5?v=Santa+Cruz+Biotechnology
Average 95 stars, based on 1 article reviews
mouse - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier

96
R&D Systems mouse anti β3 tubulin
(A) Experimental design for early-neuron marker <t>βIII-tubulin</t> detection, time course for sample acquisition and chemical treatment. (B) Representative immunofluorescences of MG at 48 h after treatments, cultured in basal growth media, CTRL: control, NMDA: exposure to NMDA 100 µM, MOCK: electroporation without plasmid, dCas9: transfection of empty plasmid, DNMT3a KD: CRISPR interference-mediated Dnmt3a knockdown, DNMT3a KD NMDA: Dnmt3a knockdown with simultaneous exposure to NMDA 100 µM; show GS (red), βIII-tubulin (green), and nuclei (DAPI, blue). (C) Percentage of positive cells to GS and βIII-tubulin, where all conditions present constant expression of GS, while βIII-tubulin percentage of positive cells were increased in DNMT3a KD and DNMT3a KD NMDA. (D) Quantification of fluorescence intensity of GS marks at 48 h after treatment, no significant differences were observed across conditions. (E) Quantification of fluorescence intensity of βIII-tubulin shows an increase in DNMT3a KD and DNMT3a KD NMDA groups, consistent with the increase in βIII-tubulin percentage of positive cells. Scale bars = 20 µm, 40X. Percentage of positive cells for each marker were presented as bar graphic for mean ± SEM from three independent experiments, counting a minimum of 10 non-overlapped fields and at least 150 cells per group. *p < 0.05, **p < 0.01, ns = no significant (one-way ANOVA with Tukey post hoc test).
Mouse Anti β3 Tubulin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti-%CE%B23+tubulin/us12454676-332-9-12?v=R%26D+Systems
Average 96 stars, based on 1 article reviews
mouse anti β3 tubulin - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier

93
R&D Systems nl557 conjugated mouse anti β3 tubulin antibody
(A) Experimental design for early-neuron marker <t>βIII-tubulin</t> detection, time course for sample acquisition and chemical treatment. (B) Representative immunofluorescences of MG at 48 h after treatments, cultured in basal growth media, CTRL: control, NMDA: exposure to NMDA 100 µM, MOCK: electroporation without plasmid, dCas9: transfection of empty plasmid, DNMT3a KD: CRISPR interference-mediated Dnmt3a knockdown, DNMT3a KD NMDA: Dnmt3a knockdown with simultaneous exposure to NMDA 100 µM; show GS (red), βIII-tubulin (green), and nuclei (DAPI, blue). (C) Percentage of positive cells to GS and βIII-tubulin, where all conditions present constant expression of GS, while βIII-tubulin percentage of positive cells were increased in DNMT3a KD and DNMT3a KD NMDA. (D) Quantification of fluorescence intensity of GS marks at 48 h after treatment, no significant differences were observed across conditions. (E) Quantification of fluorescence intensity of βIII-tubulin shows an increase in DNMT3a KD and DNMT3a KD NMDA groups, consistent with the increase in βIII-tubulin percentage of positive cells. Scale bars = 20 µm, 40X. Percentage of positive cells for each marker were presented as bar graphic for mean ± SEM from three independent experiments, counting a minimum of 10 non-overlapped fields and at least 150 cells per group. *p < 0.05, **p < 0.01, ns = no significant (one-way ANOVA with Tukey post hoc test).
Nl557 Conjugated Mouse Anti β3 Tubulin Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti-%CE%B23+tubulin/pm40967452-198-63-69?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
nl557 conjugated mouse anti β3 tubulin antibody - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier

Image Search Results


(A) Experimental design for early-neuron marker βIII-tubulin detection, time course for sample acquisition and chemical treatment. (B) Representative immunofluorescences of MG at 48 h after treatments, cultured in basal growth media, CTRL: control, NMDA: exposure to NMDA 100 µM, MOCK: electroporation without plasmid, dCas9: transfection of empty plasmid, DNMT3a KD: CRISPR interference-mediated Dnmt3a knockdown, DNMT3a KD NMDA: Dnmt3a knockdown with simultaneous exposure to NMDA 100 µM; show GS (red), βIII-tubulin (green), and nuclei (DAPI, blue). (C) Percentage of positive cells to GS and βIII-tubulin, where all conditions present constant expression of GS, while βIII-tubulin percentage of positive cells were increased in DNMT3a KD and DNMT3a KD NMDA. (D) Quantification of fluorescence intensity of GS marks at 48 h after treatment, no significant differences were observed across conditions. (E) Quantification of fluorescence intensity of βIII-tubulin shows an increase in DNMT3a KD and DNMT3a KD NMDA groups, consistent with the increase in βIII-tubulin percentage of positive cells. Scale bars = 20 µm, 40X. Percentage of positive cells for each marker were presented as bar graphic for mean ± SEM from three independent experiments, counting a minimum of 10 non-overlapped fields and at least 150 cells per group. *p < 0.05, **p < 0.01, ns = no significant (one-way ANOVA with Tukey post hoc test).

Journal: PLOS One

Article Title: Targeted knockdown of DNA methyltransferase 3a (DNMT3a) unlocks dedifferentiation and neurogenic potential in mouse retinal Müller glia

doi: 10.1371/journal.pone.0337891

Figure Lengend Snippet: (A) Experimental design for early-neuron marker βIII-tubulin detection, time course for sample acquisition and chemical treatment. (B) Representative immunofluorescences of MG at 48 h after treatments, cultured in basal growth media, CTRL: control, NMDA: exposure to NMDA 100 µM, MOCK: electroporation without plasmid, dCas9: transfection of empty plasmid, DNMT3a KD: CRISPR interference-mediated Dnmt3a knockdown, DNMT3a KD NMDA: Dnmt3a knockdown with simultaneous exposure to NMDA 100 µM; show GS (red), βIII-tubulin (green), and nuclei (DAPI, blue). (C) Percentage of positive cells to GS and βIII-tubulin, where all conditions present constant expression of GS, while βIII-tubulin percentage of positive cells were increased in DNMT3a KD and DNMT3a KD NMDA. (D) Quantification of fluorescence intensity of GS marks at 48 h after treatment, no significant differences were observed across conditions. (E) Quantification of fluorescence intensity of βIII-tubulin shows an increase in DNMT3a KD and DNMT3a KD NMDA groups, consistent with the increase in βIII-tubulin percentage of positive cells. Scale bars = 20 µm, 40X. Percentage of positive cells for each marker were presented as bar graphic for mean ± SEM from three independent experiments, counting a minimum of 10 non-overlapped fields and at least 150 cells per group. *p < 0.05, **p < 0.01, ns = no significant (one-way ANOVA with Tukey post hoc test).

Article Snippet: After that the samples were incubated with following primary antibodies: mouse monoclonal anti-βlll tubulin antibody (Santa Cruz sc-80005) (1:300); rabbit polyclonal anti-GS antibody (Abcam ab73593) (1:300); mouse monoclonal anti-nestin antibody (Santa Cruz sc-23927) (1:200); rabbit polyclonal anti-Lin28 (Abcam ab46020) (1:200) diluted in 1:3 blocking solution at 4°C overnight.

Techniques: Marker, Cell Culture, Control, Electroporation, Plasmid Preparation, Transfection, CRISPR, Knockdown, Expressing, Fluorescence

(A) Experimental design for early-neuron marker βIII-tubulin induction with GABA after CRISPRi transfection, showing the time course followed for sample acquisition and chemical treatment. (B) Representative images for immunofluorescence of MG cultured 48 h in growth medium and then cultured for 9 days in differentiation medium with GABA 100 µM. Images show GS (red), βIII-tubulin (green), and nuclei (DAPI, blue). Control conditions (CTRL, MOCK, dCas9) maintain GS expression with negligible βIII-tubulin signal. Meanwhile in NMDA, DNMT3a KD and DNMT3a KD NMDA βIII-tubulin positive cells were present, and GS expression was maintained. CTRL: control, NMDA: exposure to NMDA 100 µM, MOCK: electroporation without plasmid, dCas9: transfection of empty plasmid, DNMT3a KD: CRISPR interference-mediated Dnmt3a knockdown, DNMT3a KD NMDA: Dnmt3a knockdown with simultaneous exposure to NMDA 100 µM. Scale bars = 20 µm, 40X. (C) Quantification of percentage of positive cells to each marker, all conditions present constant expression of GS, while βIII-tubulin percentage of positive cells were increased in NMDA, DNMT3a KD and DNMT3a KD NMDA. (D) Quantification of fluorescence intensity of GS marks at 48 h after treatment, no significant differences were observed across conditions. (E) Quantification of fluorescence intensity of βIII-tubulin shows an increase in NMDA, DNMT3a KD and DNMT3a KD NMDA groups. Data were presented as violin plots of at least three independent experiments, counting a minimum of 10 non-overlapped fields and at least 150 cells per group. *p < 0.05, ***p < 0.001, ns = no significant (one-way ANOVA with Tukey’s post hoc test).

Journal: PLOS One

Article Title: Targeted knockdown of DNA methyltransferase 3a (DNMT3a) unlocks dedifferentiation and neurogenic potential in mouse retinal Müller glia

doi: 10.1371/journal.pone.0337891

Figure Lengend Snippet: (A) Experimental design for early-neuron marker βIII-tubulin induction with GABA after CRISPRi transfection, showing the time course followed for sample acquisition and chemical treatment. (B) Representative images for immunofluorescence of MG cultured 48 h in growth medium and then cultured for 9 days in differentiation medium with GABA 100 µM. Images show GS (red), βIII-tubulin (green), and nuclei (DAPI, blue). Control conditions (CTRL, MOCK, dCas9) maintain GS expression with negligible βIII-tubulin signal. Meanwhile in NMDA, DNMT3a KD and DNMT3a KD NMDA βIII-tubulin positive cells were present, and GS expression was maintained. CTRL: control, NMDA: exposure to NMDA 100 µM, MOCK: electroporation without plasmid, dCas9: transfection of empty plasmid, DNMT3a KD: CRISPR interference-mediated Dnmt3a knockdown, DNMT3a KD NMDA: Dnmt3a knockdown with simultaneous exposure to NMDA 100 µM. Scale bars = 20 µm, 40X. (C) Quantification of percentage of positive cells to each marker, all conditions present constant expression of GS, while βIII-tubulin percentage of positive cells were increased in NMDA, DNMT3a KD and DNMT3a KD NMDA. (D) Quantification of fluorescence intensity of GS marks at 48 h after treatment, no significant differences were observed across conditions. (E) Quantification of fluorescence intensity of βIII-tubulin shows an increase in NMDA, DNMT3a KD and DNMT3a KD NMDA groups. Data were presented as violin plots of at least three independent experiments, counting a minimum of 10 non-overlapped fields and at least 150 cells per group. *p < 0.05, ***p < 0.001, ns = no significant (one-way ANOVA with Tukey’s post hoc test).

Article Snippet: After that the samples were incubated with following primary antibodies: mouse monoclonal anti-βlll tubulin antibody (Santa Cruz sc-80005) (1:300); rabbit polyclonal anti-GS antibody (Abcam ab73593) (1:300); mouse monoclonal anti-nestin antibody (Santa Cruz sc-23927) (1:200); rabbit polyclonal anti-Lin28 (Abcam ab46020) (1:200) diluted in 1:3 blocking solution at 4°C overnight.

Techniques: Marker, Transfection, Immunofluorescence, Cell Culture, Control, Expressing, Electroporation, Plasmid Preparation, CRISPR, Knockdown, Fluorescence

Representative immunofluorescences of MG at 48 h and 9 days after CRISPRi transfection with simultaneous addition of NMDA 100 µM, where we could observe coexpresión of glial (GS, red) and early-neuronal (βIII-tubulin, green) markers indicating a partial cell reprogramming. DNMT3a KD NMDA: Dnmt3a knockdown with simultaneous exposure to NMDA 100 µM; show GS (red), βIII-tubulin (green), and nuclei (DAPI, blue). Scale bars = 50 µm, 40X.

Journal: PLOS One

Article Title: Targeted knockdown of DNA methyltransferase 3a (DNMT3a) unlocks dedifferentiation and neurogenic potential in mouse retinal Müller glia

doi: 10.1371/journal.pone.0337891

Figure Lengend Snippet: Representative immunofluorescences of MG at 48 h and 9 days after CRISPRi transfection with simultaneous addition of NMDA 100 µM, where we could observe coexpresión of glial (GS, red) and early-neuronal (βIII-tubulin, green) markers indicating a partial cell reprogramming. DNMT3a KD NMDA: Dnmt3a knockdown with simultaneous exposure to NMDA 100 µM; show GS (red), βIII-tubulin (green), and nuclei (DAPI, blue). Scale bars = 50 µm, 40X.

Article Snippet: After that the samples were incubated with following primary antibodies: mouse monoclonal anti-βlll tubulin antibody (Santa Cruz sc-80005) (1:300); rabbit polyclonal anti-GS antibody (Abcam ab73593) (1:300); mouse monoclonal anti-nestin antibody (Santa Cruz sc-23927) (1:200); rabbit polyclonal anti-Lin28 (Abcam ab46020) (1:200) diluted in 1:3 blocking solution at 4°C overnight.

Techniques: Transfection, Knockdown